A Study of Continuous Oral Contraceptives and Doxycycline
Completed
Oregon Health and Science University
N/A
2007-05-01
The purpose of this study is to learn if the study drug, doxycycline, can decrease the amount
of unplanned vaginal bleeding that women commonly experience when taking combined oral
contraception (COC)- pills with estrogen and progestin - in a continuous fashion - no
hormone-free week. The study drug, doxycycline, is an antibiotic used commonly for many
conditions (i.e. acne, Chlamydia infections, pneumonia) and can be safely used on a daily
basis. Doxycycline has been shown to decrease unplanned vaginal bleeding in progestin-only
contraception but has not been studied in combined hormonal contraception.
Study Of Lybrel In Relation To Venous Thromboembolism
Completed
Boston Collaborative Drug Surveillance Program
2007-07-01
Lybrel® is an oral contraceptive that delivers low doses of levonorgestrel and ethinyl
estradiol (90 μg/20 μg). Lybrel is taken on a continuous basis without a placebo or pill-free
interval to inhibit menstrual cycle bleeding by delivering a steady level of the 2 hormones
for as long as the drug is used. Lybrel was marketed in the US in July of 2007. The objective
of this database case-control study is to estimate the risk of idiopathic VTE (deep vein
thrombosis and pulmonary embolism) in current users of Lybrel (ethinyl estradiol
20ug/levonorgestrel 90ug) compared to current users of other oral contraceptives containing
20μg of ethinyl estradiol.
Study Of Lybrel In Relation To Venous Thromboembolism
Completed
Pfizer
2007-07-01
Lybrel® is an oral contraceptive that delivers low doses of levonorgestrel and ethinyl
estradiol (90 μg/20 μg). Lybrel is taken on a continuous basis without a placebo or pill-free
interval to inhibit menstrual cycle bleeding by delivering a steady level of the 2 hormones
for as long as the drug is used. Lybrel was marketed in the US in July of 2007. The objective
of this database case-control study is to estimate the risk of idiopathic VTE (deep vein
thrombosis and pulmonary embolism) in current users of Lybrel (ethinyl estradiol
20ug/levonorgestrel 90ug) compared to current users of other oral contraceptives containing
20μg of ethinyl estradiol.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
